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Localization, Age- and Site-Dependent Expression,
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Dehydrogenase Type 1 in Skin
Ana Tiganescu1, Elizabeth A. Walker1, Rowan S. Hardy1, Andrew E. Mayes2 and Paul M. Stewart1
Glucocorticoids (GCs) are highly detrimental to skin integrity and function both when applied topically for anti-
inflammatory treatments and during conditions of circulating excess, e.g., Cushing’s syndrome. Within target
tissues, GC availability is regulated at a prereceptor level, independently of systemic levels, by isozymes of
11b-hydroxysteroid dehydrogenase (11b-HSD) that interconvert active cortisol and inactive cortisone. Many of
the adverse effects of GCs on skin are also reminiscent of the natural aging process. 11b-HSD1 (which activates
cortisol), but not 11b-HSD2 (which inactivates cortisol), was expressed in epidermal keratinocytes and dermal
fibroblasts in human skin and also in outer hair follicle root sheath cells in murine skin. 11b-HSD1 activity was
present ex vivo in both species and increased with age in human skin tissue explants. In primary human dermal
fibroblasts (HDF) from both photoprotected and photoexposed sites, 11b-HSD1 also increased with donor
age. Additionally, photoexposed HDF displayed higher 11b-HSD1 mRNA expression than donor-matched
photoprotected HDF. GC treatment of HDF caused upregulation of 11b-HSD1 mRNA levels independent of
donor age or site. The age- and site-associated increase in dermal 11b-HSD1, and the ensuing increased local
GC activation, may contribute to the adverse changes in skin morphology and function associated with
chronological aging and photoaging.
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INTRODUCTION
The demography of industrialized countries is currently
undergoing a major shift toward aging populations (Doyle
et al., 2009). As life expectancy continues to rise, current
research is focused on prolonging good health in later life,
thus enabling people to remain in employment for longer and
achieve a higher quality of life following retirement.
Skin disorders are a common source of morbidity in the
elderly with most people more than 65 years having one
condition and many having two or more (Kligman and
Koblenzer, 1997). These occur as a result of age-related
degeneration causing persistent dryness and itching (Harvell
and Maibach, 1994), cutaneous infection (Schwartz et al.,
2006), autoimmune disorders (Farage et al., 2009), and
vascular complications (Chang et al., 2002a; Chung and Eun,
2007). Skin aging is generally subdivided into two categories;
intrinsic and extrinsic.
Intrinsic skin aging factors are typically nonmodifiable and
include ethnicity, anatomical site differences, and chrono-
logical changes such as the hormonal alterations following
menopause (Farage et al., 2008). Intrinsically aged skin
(such as inner arm, hip, thigh, and buttock) is smooth and
unblemished with epidermal and dermal atrophy, flattening
of epidermal rete ridges, and reduced numbers of dermal
fibroblasts and mast cells (Fenske and Lober, 1986; Roupe,
2001). Epidermal turnover time is twice as long in the elderly
contributing to slower wound-healing rates (Grove and
Kligman, 1983). Additionally, there is an increase in dermal
collagen fibril numbers and an increase in the ratio of
collagen III to collagen I protein isoforms (Lovell et al., 1987).
Conversely, extrinsic skin aging factors are largely modifi-
able with lifestyle choices (e.g., smoking and alcohol
consumption) having a large role, but the greatest contributing
factor is UV light exposure accounting for up to 80% of visible
skin aging (Uitto, 1997; Farage et al., 2008). Photoexposed
skin (such as outer arm, face, and hands) displays rhytides,
pigmented or depigmented lesions, a pronounced loss of tone
and elasticity, increased fragility, areas of purpura, and benign
lesions. Photoexposed skin contains greater numbers of mast
cells, macrophages, and has a greater mononuclear cell
infiltrate than intrinsically aged skin, which contributes to the
observed atrophy (Bosset et al., 2003). There are conflicting
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studies regarding changes in epidermal thickness with age
(Whitton and Everall, 1973; Lavker, 1979); however, thickness
was found to be greater in photoexposed versus photopro-
tected skin (El-Domyati et al., 2002).
Interestingly, many of the adverse effects associated with
cutaneous aging are also inducible by glucocorticoids (GCs;
Oikarinen and Autio, 1991; Kolbe et al., 2001; Schoepe
et al., 2006). Systemically, cortisol is secreted in response
to stress through a regulated process via the hypothalamo–
pituitary–adrenal axis. Cortisol binds to the ubiquitously
expressed GC receptor (GR) to modulate gene transcription.
However, within target tissues, cortisol concentrations
are regulated at a prereceptor level by isozymes of 11b-
hydroxysteroid dehydrogenase (11b-HSD). The bidirectional
enzyme 11b-HSD type 1 (11b-HSD1) functions predomi-
nantly as an oxoreductase; activating cortisol from inactive
cortisone (Tomlinson et al., 2004). 11b-HSD1 localizes to
the endoplasmic reticulum membrane and requires the
cofactor NADPH for oxoreductase activity—provided by
the endoluminal enzyme hexose-6-phosphate dehydrogenase
(H6PDH; Hewitt et al., 2005).
11b-HSD1 is widely expressed, and although its role in
tissues such as liver and adipose has been extensively studied
(with relevance to insulin resistance and central obesity;
Bujalska et al., 2007; Tomlinson et al., 2008; Morgan et al.,
2009), skin has not been investigated in great detail. This
study aimed to characterize the localization and regulation of
11b-HSD1 in human skin and analyze differences in the
expression patterns between old, young, photoexposed, and
photoprotected human dermal fibroblasts (HDF), studies that
collectively may shed light on the pathogenesis of skin aging.
RESULTS
Localization of 11b-HSD1 in skin
Immunolocalization of 11b-HSD1 in mouse skin was observed
primarily in epidermal epithelial cells (keratinocytes), dermal
mesenchymal cells (fibroblasts), and the outer root sheath of
hair follicles (Figure 1a and c). Mouse liver sections were used
as a positive control and displayed characteristic staining
around the central vein (Figure 1e). No staining was detected
with isotype control (Figure 1b and f) or in sections obtained
from global 11b-HSD1 knockout mice (Figure 1d).
11b-HSD1 localization in human skin was found to vary
depending on the age of the donor. Epidermal keratinocyte
staining was observed in skin sections from pre-menopausal
women (Figure 2a, c, and e) and to a lesser extent in sections
from post-menopausal women (Figure 2b, d, and f). Conversely,
dermal staining was more prominent in post-menopausal
sections (Figure 2b, d, and f). Positive staining was absent or
much reduced with isotype control in both pre-menopausal and
post-menopausal sections (data not shown).
11b-HSD2 expression was undetectable by immunohis-
tochemistry in human or mouse sections (human kidney
served as a positive control, data not shown).
Characterization of 11b-HSD activity in skin tissue explants
Murine skin tissue explants displayed 11b-HSD1 oxoreduc-
tase activity of 327±60 fmolmg–1 per hour (mean±SE fmol
of steroid produced per milligram of total protein per hour,
n¼12, Figure 3a) when incubated for 24 h with 200 nM
11-dehydrocorticosterone (11-DHC) (inactive GC). This was
reduced by480% following coincubation with the 11b-HSD
inhibitor glycyrrhetinic acid (n¼ 10, Figure 3a). 11b-HSD1
knockout mouse skin explants had negligible activity (n¼19,
Figure 3a). Additionally, 11b-HSD dehydrogenase activity
was undetectable in wild-type mouse skin explants following
incubation with corticosterone (active GC).
Activity was measured in site-matched human skin
explants from donors of varying age. Following 24 h
incubation with 100 nM cortisone, oxoreductase activity was
9.6±3.6 fmolmg–1 per hour (n¼ 15), B10-fold lower to that
seen in mouse skin with a trend toward increased activity
with age (P¼ 0.56 Figure 3b). In contrast to mouse skin,
dehydrogenase activity was also detected (22.1±12.0,
n¼13), but was not correlated with age (data not shown).
11b-HSD, GRa, and H6PDH mRNA expression in dermal
fibroblasts
11b-HSD1, 11b-HSD2, GRa, and H6PDH mRNA levels were
analyzed in site-matched primary cultures of HDF (all mRNA
data presented as mean DCt±SD). Two separate donor-
matched sites were investigated; photoprotected inner upper
arm and photoexposed outer upper arm, and a positive
correlation between 11b-HSD1 mRNA expression and age
*
Figure 1. Expression of 11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1) by immunohistochemistry in murine skin. Expression was
confirmed in epidermal keratinocytes (arrow; a and c), dermal fibroblasts
(arrowhead; c), and outer root sheath cells (asterisk; a and c). Staining was
negligible in isotype control (b) and 11b-HSD1 knockout (d) sections. Mouse
liver was used as positive control tissue (e) in which staining was also ablated
with isotype control (f). Scale bar¼ 100mm.
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was observed (Po0.01, 21–78 years, n¼19, Figure 3c).
These mRNA expression data support the whole skin oxo-
reductase activity results detailed above (Figure 3b). Interest-
ingly, we also observed that donor-matched photoexposed
HDF had on average 5-fold greater levels of 11b-HSD1
mRNA than photoprotected HDF (Figure 3d; Po0.05, n¼ 7).
GRa and H6PDH mRNA was found to be highly expressed
and did not correlate with age or site (DCt 9.3±1.2 (n¼18)
and 12.0±0.86 (n¼ 19), respectively), whereas expression of
11b-HSD2 mRNA was negligible and did not correlate with
age or site (DCt 24.3±2.1, n¼19).
GC regulation of 11b-HSDs and GRa in dermal fibroblasts
11b-HSD1 mRNA was shown to be upregulated by GC
treatment in a dose-dependent manner (Figure 4a). Upregula-
tion was observed in all nine lines tested and was inde-
pendent of donor age and site (although differences in the
magnitude of the response ranging from 3-fold to 20-fold
were noted, data not shown). Treatment of HDF with 100 nM
cortisol resulted in a 5-fold increase in 11b-HSD1 mRNA
levels (relative to untreated control), whereas 11b-HSD2 and
GRa mRNA were both downregulated by 4- and 2.5-fold,
respectively (Figure 4b). H6PDH was not regulated by GC
treatment. Following treatment, the positive correlation
between 11b-HSD1 mRNA and age was still apparent
(Figure 4c). Although 11b-HSD1 activity was undetectable
in all but one (73-year-old female) untreated HDF lines
Figure 2. Expression of 11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1) by immunohistochemistry in human skin. Expression was
observed primarily in the epidermal layer of premenopausal donors
(n¼3) with limited dermal expression (a, c, and e). Expression was increased
in the dermal layer of post-menopausal donors (n¼ 3) compared with
premenopausal samples (b, d, and f). Scale bar¼ 100mm.
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Figure 3. Increased 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1)
activity and mRNA levels with age and level of photoexposure. (a) 11b-
HSD1 activity was detectable in wild-type (WT) mouse skin tissue explants
(n¼12), reduced by 480% with the 11b-HSD inhibitor glycyrrhetinic acid
(n¼10), and undetectable in knockout (KO) mice (n¼ 19). (b) Human skin
tissue explants demonstrated a trend toward increased 11b-HSD1 activity
with donor age (n¼15, P¼0.56). (c) 11b-HSD1 mRNA in human dermal
fibroblasts (HDFs) showed a positive correlation with donor age following
normalizing to 18S (n¼19, Po0.01). (d) 11b-HSD1 mRNA was B5-fold
higher in photoexposed compared with donor-matched photoprotected
HDFs (n¼ 7, mean DCt±SD 23.1±2.3 and 20.8±2.9 for photoprotected
and photoexposed samples, respectively). Significance: ***Po0.001;
**Po0.01; *Po0.05.
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(data not shown), interestingly, activity was readily detectable
in old (but not young) cells after GC treatment (Figure 4d).
DISCUSSION
Very few previous studies have described the presence and
activity of 11b-HSD1 in skin (Hammami and Siiteri, 1991;
Andersson et al., 2007 and Hennebert et al., 2007). Here, we
present data describing the localization of 11b-HSD1 to
dermal and epidermal components of mouse and human skin.
We provide evidence for an age-dependent 11b-HSD1 activity
in human skin and suggest this may be partly due to increased
mRNA levels with age in HDF. We also report higher levels of
11b-HSD1 mRNA in HDF derived from photoexposed skin
compared with matched photoprotected skin and a site- and
age-independent upregulation following GC treatment.
We (and others) have previously reported the expression
and a functional role of 11b-HSD1 in a variety of tissues and
primary cells, including liver (Ricketts et al., 1998), adipose
(Bujalska et al., 2007), pancreas (Swali et al., 2008), eye
(Onyimba et al., 2006), synovium (Hardy et al., 2008), and
bone (Cooper et al., 2002). However, studies characterizing
this enzyme in skin tissue and cells are extremely limited.
This is somewhat surprising considering the plethora of
existing data describing the adverse effects of GCs on skin
morphology and function and the prolific use of topical and
systemic GC therapies.
GCs induce a thinning of the dermis and epidermis (Mills
and Marks, 1993; Josse et al., 2009), reduced size and
proliferative capacity of keratinocytes and dermal fibroblasts
(Kolbe et al., 2001), and cause a reduction in extracellular
matrix components such as hyaluronan and collagen
(Nuutinen et al., 2001; Gebhardt et al., 2009). These changes
compromise barrier function, tensile strength, and structural
integrity (Kao et al., 2003), resulting in skin that is thinner,
dryer, and more prone to shearing.
The localization of 11b-HSD1 in murine skin has not
previously been reported. Our immunohistochemical studies
define 11b-HSD1 expression to epidermal keratinocytes,
dermal fibroblasts, and hair outer root sheath. We demon-
strated similar results in human skin where we also observed
greater dermal expression in post-menopausal donor-derived
tissue sections. A recent study also reported 11b-HSD1
localization to the stratum corneum, dermal fibroblasts,
and hair follicle-associated cells (Hennebert et al., 2007).
Although this group did not specify donor age, the data they
report are largely in concordance with our findings. How-
ever, stratum corneum expression was not observed in our
sections and this is likely due to differences in skin tissue
source (abdominal versus arm), highlighting the importance
for site- and donor-matched sampling.
11b-HSD1 activity assays conducted in human skin tissue
explants revealed a trend toward increased oxoreductase
activity with donor age, whereas dehydrogenase activity
levels were found to be greater but did not correlate with
age. Murine skin tissue explant oxoreductase activity was
B10-fold higher than that observed in human skin tissue
explants, whereas dehydrogenase activity was undetectable.
The lack of dehydrogenase activity in mouse skin is likely
n
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Figure 4. Regulation of glucocorticoid-responsive gene expression in dermal
fibroblasts. (a) Primary human dermal fibroblast (HDF) 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1) mRNA was upregulated in a dose-dependent
manner by cortisol treatment in all lines tested (n¼ 9). (b) Primary HDF 11b-
HSD1 mRNA was upregulated, whereas 11b-HSD2 and glucocorticoid receptor
alpha (GRa) mRNA levels were downregulated after 24-hour 100nM cortisol
treatment. Hexose-6-phosphate dehydrogenase (H6PDH) mRNAwas unaffected.
Significance: ***Po0.001; **Po0.01. Tabulated values represent mean DCt
values normalized to 18S±SD. (c) Glucocorticoid (GC)-treated 11b-HSD1
mRNA in site-matched HDF showed a positive correlation with donor age
(n¼ 10, Po0.01). (d) GC-treated site-matched HDF demonstrated increased
11b-HSD1 activity with donor age (n¼ 10, P¼o0.01 Spearman’s correlation).
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because of the absence of eccrine sweat glands that express
11b-HSD2 (Bocchi et al., 2004), which are common in
human skin but only occur in mouse paw pad skin. Reduced
levels of 11b-HSD2 in full-thickness mouse skin may also
explain the higher 11b-HSD1 oxoreductase activity observed,
as a proportion of the activated cortisol in human skin will be
interconverted back to cortisone by 11b-HSD2, resulting in
an apparently lower activity.
The results obtained from full-thickness skin activity assays
were endorsed by 11b-HSD1 mRNA analysis in primary
cultures of HDFs, which also demonstrated an increase in
mRNA levels with donor age. Although studies investigating
age-related changes in 11b-HSD1 are limited, they support
observations presented in this paper. Li et al. (2007) recently
reported that 11b-HSD1 expression was higher in human
omental adipose tissue (but not in subcutaneous) obtained
from adults compared with children. Studies conducted in
primary human osteoblasts also showed a positive correlation
between 11b-HSD1 activity and age (Cooper et al., 2002).
These studies concluded that age-related increases in 11b-
HSD1 may contribute to age-related development of adipos-
ity and decreases in bone mineral density leading to
osteoporosis. Similarly in skin, we suggest that the adverse
changes in morphology and function associated with aging
may, in part, be due to increased local GC production.
We have also shown that GC treatment of HDF increases
11b-HSD1 mRNA in a dose-dependent manner and con-
comitantly reduces 11b-HSD2 mRNA, resulting in a positive
feedback loop that further enhances GC activation. This
could have implications during topical and systemic GC
therapies in which the associated side effects of treatment
may be exacerbated by additional generation of cortisol
locally. As 11b-HSD1 increases with age, elderly patients are
likely to be more severely affected by this amplification
process, supported by our observation of readily detectable
11b-HSD1 activity in HDF from older (but not younger)
donors following cortisol treatment. Selective 11b-HSD1
inhibitors are already under development and investigation as
therapeutic agents for patients with obesity and diabetes
mellitus (Tomlinson and Stewart, 2007). It is exciting to
speculate that 11b-HSD1 inhibitors may also have applica-
tions in minimizing side effects associated with topical GC
therapy particularly in the elderly.
The mechanisms driving the increase in 11b-HSD1 activity
and expression in skin with age remain to be elucidated;
however, the age-related decline in growth hormone and IGF-1
levels may offer an explanation. Growth hormone, through
IGF-1, inhibits 11b-HSD1 activity causing an increase in cortisol
activation as its levels decline with age (Moore et al., 1999).
We also report greater 11b-HSD1 mRNA levels in donor-
matched photoexposed HDF compared with photoprotected.
Previous studies have also shown differential gene expression
patterns in HDF based on site (Rinn et al., 2002 and Chang
et al., 2002b)—this is not surprising considering site-specific
differences in skin function and morphology (Chipev and
Simon, 2002 and Gambichler et al., 2006). However, a
difference based on the level of photoexposure for 11b-HSD1
is, to our knowledge, previously unreported and suggests that
the increased levels in photoexposed skin may contribute to
the morphological alterations associated with sun damage.
The expression of 11b-HSD1 within the epidermis and
dermis represents an exciting mechanism in regulating GC
hormone action within skin. Age- and photoexposure-related
increases in expression, together with upregulation following
GC exposure, suggest that this enzyme may have an
etiological role in skin aging. If so, dermal 11b-HSD1
inhibitors may offer beneficial applications in minimizing
prolonged side effects associated with topical GC therapy in
the elderly, as well as reducing the impact of increased local
GC exposure with chronological aging and photoaging on
adverse dermal outcomes.
MATERIALS AND METHODS
Declarations
Studies presented in this paper were approved by the following ethics
committees: French Central Ethics Committee. The study was conducted
according to the Declaration of Helsinki Principles. All participants gave
their written informed consent before study enrolment.
Immunohistochemistry
Immunohistochemical analyses were performed on 5-mm paraffin-
embedded sections of mouse and human full-thickness skin tissue
mounted on charged slides. Mouse skin (surplus tissue from other
studies) was obtained from both wild-type animals and from animals
with a global deletion of 11b-HSD1 (knockout) by dissection of
shaved skin from the lower dorsal region followed by fixation in 10%
neutral-buffered formalin. Human forearm samples were obtained
from premenopausal (n¼ 3) and post-menopausal (n¼ 3) healthy
volunteers by punch biopsy following ethical approval.
Antigen retrieval was performed on dewaxed and rehydrated
slides using 0.2 trypsin in 1% (w/v) calcium chloride for
30minutes at room temperature followed by endogenous peroxidase
inactivation with hydrogen peroxide for 15minutes. Slides were
rinsed in water and blocked with 10% goat serum diluted in
blocking buffer (1% IgG-free BSA, 0.1% Tween-20 in phosphate-
buffered saline) for 1 hour. Sections were incubated with rabbit anti-
11b-HSD1 primary antibody (Cayman Chemical, MI) diluted 1:20
and sheep anti-11b-HSD2 (Binding Site, Birmingham, UK) diluted
1:100 in blocking buffer for 1 hour. Negative control sections were
incubated with rabbit or sheep IgG serum (isotype control) at the
same concentration as the primary antibody. The positive control
tissue sections used were mouse liver (for 11b-HSD1) and human
kidney (for 11b-HSD2). Sections were washed (3 10minutes)
in phosphate-buffered saline–Tween (0.1%) before incubating with
horseradish peroxidase-conjugated goat anti-rabbit (Dako, Glostrup,
Denmark) or rabbit anti-sheep (Binding Site) secondary antibody
diluted 1:200 for 30minutes. The sections were then washed again (as
before) and finally incubated with 3,30-diaminobenzidine (Vector-
Labs, Burlingame, CA) until development of a brown precipitate
(5minutes). Slides were dehydrated and mounted for storage.
11b-HSD enzyme assays in skin tissue explants
Approximately 6mg tissue was used per assay. Mouse tissue was
obtained as detailed above, whereas human samples were obtained
(with ethical consent) from patients undergoing elective knee
replacement surgery.
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Dehydrogenase activity (cortisol to cortisone or corticosterone
to 11-DHC conversion in human or mouse tissue respectively)
was assessed using 100 nM cortisol/corticosterone diluted in 0.5ml
media (in glass tubes) with tracer amounts of [3H] cortisol/11-DHC
(specific activity 74.0Cimmol–1; NEN, Boston, MA) at 37 1C
for 24 hours.
Conversion of cortisone to cortisol or 11-DHC to corticosterone
(oxoreductase) was analyzed by incubating cells with 100 nM
cortisone/11-DHC and tracer amounts of [3H] cortisone/corticoster-
one synthesized in-house (Bujalska et al., 2002). Glycyrrhetinic acid
(2mM) was used to inhibit 11b-HSD1. Following incubation, steroids
were extracted from the medium with dichloromethane, separated
by thin-layer chromatography with chloroform/ethanol (92:8) and
the fractional conversion of steroids calculated by scanning analysis
with a Bioscan 2000 radioimageing detector (Bioscan, Washington,
DC). All assays were conducted in duplicate for each skin sample.
Primary dermal fibroblast culture and GC treatment
Primary HDFs from photoprotected (inner upper arm) and photo-
exposed (outer upper arm) from donors of varying age were cultured
from punch biopsy tissue explants following ethical approval.
Briefly, cells were grown in RPMI-1640 media supplemented
with 10% fetal calf serum, 2mmol l–1 L-glutamine, 1% Pen-Strep,
1% sodium pyruvate, and 1% nonessential amino acids. Upon
confluence the cells were transferred to a T75 flask and passaged at a
ratio of 1:3 at 80% confluence as required.
For GC treatment, cells were seeded into six-well plates at 70%
confluence and incubated at 37 1C and 5% CO2 to adhere overnight.
Optimum dose was determined by dose response to be 100 nM.
Subsequently, cells were treated for 48 hours with 100 nM (200 pmol)
cortisol with nontreated cells as controls (in duplicate).
GC-treated/untreated 11b-HSD1 activity was determined in six-
well plated cells as for whole tissue (detailed above) in 2ml media.
For GC-treated cells, treatment was maintained for the duration
of the assay (24 hours, 37 1C). Total protein was determined using a
commercially available protein assay (BioRad, Hemel Hempstead,
UK) and activity expressed as fmolmg–1 per hour.
HDF RNA extraction and reverse transcription
Total RNA was extracted from fresh cultures of HDF using a single-
step extraction method (Tri-Reagent; Sigma-Aldrich, Gillingham, UK).
RNA integrity was assessed by electrophoresis on 1% (w/v) agarose
gel, and quantity was determined spectrophotometrically at OD260.
A measure of 1 mg of total RNA was reverse transcribed in 25 ml
total volume using TaqMan Reverse Transcription Reagents (Applied
Biosystems, Warrington, UK) according to the manufacturer’s guidelines.
The reaction was terminated by heating the cDNA to 95 1C for 5minutes
and stored at 20 1C until required.
Real-time reverse transcriptase-PCR
11b-HSD1, 11b-HSD2, GRa, and H6PDH mRNA levels were
measured using real-time PCR using an ABI 7500 system (Perkin-
Elmer, Cambridge, UK). PCR was performed in 20 ml reactions on
96-well plates in reaction buffer containing TaqMan universal PCR
mastermix (Applied Biosystems), 900 nmol primers, 100–200 nmol
TaqMan probe, and 25–50 ng cDNA. All reactions were multiplexed
with primers specific for 18S rRNA (provided as a preoptimised mix;
Applied Biosystems) as an internal reference and were carried out in
duplicate. Data were obtained as Ct values (the cycle number at
which logarithmic PCR plots cross a calculated threshold line) and
used to determine DCt values (DCt¼Ct of the target gene minus Ct of
the internal reference, 18S). All target gene probes were labeled with
the fluorescent label 6-carboxyfluorescein, and the housekeeping
gene was labeled with the fluorescent label VIC. Reactions
were as follows: 50 1C for 2minutes, 95 1C for 10minutes, and
then 40 cycles of 95 1C for 15 seconds and 60 1C for 1minutes.
Sequences of oligonucleotide primers and probes were as follows:
(i) 11b-HSD1 antisense primer 50-AGGAAAGCTCATGGGAGGACT
AG-30, sense primer 50-ATGGTGAATATCATCATGAAAAAGATTC-30,
probe 50-CATGCTCATTCTCAACCACATCACCAACA-30; (ii) 11b-HSD2,
GRa, H6PDH, and 18S primers, and probes were obtained from
Applied Biosystems (Foster City, CA).
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